Genotypic and Phenotypic Characteristics of Co-Trimoxazole-Induced Cutaneous Adverse Reactions.
Co-trimoxazole
Drug reaction with eosinophilia and systemic symptoms
Human leukocyte antigens
Severe cutaneous adverse reactions
Stevens-Johnson syndrome
Journal
Dermatology (Basel, Switzerland)
ISSN: 1421-9832
Titre abrégé: Dermatology
Pays: Switzerland
ID NLM: 9203244
Informations de publication
Date de publication:
2023
2023
Historique:
received:
26
11
2022
accepted:
25
09
2023
medline:
7
12
2023
pubmed:
5
10
2023
entrez:
4
10
2023
Statut:
ppublish
Résumé
Co-trimoxazole has been reported as a common culprit drug for various cutaneous adverse drug reactions (CADRs). However, information on genotypic and phenotypic characteristics is still limited. We aimed to study clinical characteristics, genetic suitability, laboratory findings, and treatment outcomes in patients with co-trimoxazole-induced CADR and determine variables associated with severe cutaneous adverse reactions (SCARs). The medical records of all patients diagnosed with co-trimoxazole-induced CADR during October 2015 and October 2021 were reviewed. Clinical characteristics and laboratory investigation with an emphasis on human leukocyte antigen (HLA) class I and HLA-DRB1 results linked to subtypes of cutaneous adverse reactions were evaluated. Seventy-two patients diagnosed with co-trimoxazole-induced CADR were included in the study. Mean age at diagnosis was 38.0 ± 14.6 years old, and 72% were female. Subtypes of reactions included maculopapular eruption (MPE; 56.9%), drug reaction with eosinophilia and systemic symptoms (DRESS; 23.6%), Stevens-Johnson syndrome (SJS; 12.5%), fixed drug eruption (4.2%), and urticaria (2.8%). Characteristics that were significantly associated with SCARs included male gender (OR = 3.01, 95% CI: 1.04-8.75), HIV infection (OR = 3.48, 95% CI: 1.13-10.75), prophylactic use of co-trimoxazole (OR = 4.89, 95% CI: 1.54-15.57), and co-trimoxazole administration longer than 10 days (OR = 7.65, 95% CI: 2.57-22.78). HLA-B*38:02 was associated with co-trimoxazole-induced SJS, while HLA-A*11:01, HLA-B*13:01, and HLA-DRB1*12:01 were associated with co-trimoxazole-induced DRESS. HLA-B*52:01 was associated with co-trimoxazole-induced MPE. Co-trimoxazole could induce various phenotypes of CADRs. Genotypic and phenotypic factors that may potentially predict co-trimoxazole-induced SCARs include male gender, HIV infection, prophylactic and prolonged drug use, as well as the presence of HLA-A*11:01, HLA-B*13:01, HLA-B*38:02, or HLA-DRB1*12:01 alleles.
Sections du résumé
BACKGROUND
BACKGROUND
Co-trimoxazole has been reported as a common culprit drug for various cutaneous adverse drug reactions (CADRs). However, information on genotypic and phenotypic characteristics is still limited. We aimed to study clinical characteristics, genetic suitability, laboratory findings, and treatment outcomes in patients with co-trimoxazole-induced CADR and determine variables associated with severe cutaneous adverse reactions (SCARs).
METHODS
METHODS
The medical records of all patients diagnosed with co-trimoxazole-induced CADR during October 2015 and October 2021 were reviewed. Clinical characteristics and laboratory investigation with an emphasis on human leukocyte antigen (HLA) class I and HLA-DRB1 results linked to subtypes of cutaneous adverse reactions were evaluated.
RESULTS
RESULTS
Seventy-two patients diagnosed with co-trimoxazole-induced CADR were included in the study. Mean age at diagnosis was 38.0 ± 14.6 years old, and 72% were female. Subtypes of reactions included maculopapular eruption (MPE; 56.9%), drug reaction with eosinophilia and systemic symptoms (DRESS; 23.6%), Stevens-Johnson syndrome (SJS; 12.5%), fixed drug eruption (4.2%), and urticaria (2.8%). Characteristics that were significantly associated with SCARs included male gender (OR = 3.01, 95% CI: 1.04-8.75), HIV infection (OR = 3.48, 95% CI: 1.13-10.75), prophylactic use of co-trimoxazole (OR = 4.89, 95% CI: 1.54-15.57), and co-trimoxazole administration longer than 10 days (OR = 7.65, 95% CI: 2.57-22.78). HLA-B*38:02 was associated with co-trimoxazole-induced SJS, while HLA-A*11:01, HLA-B*13:01, and HLA-DRB1*12:01 were associated with co-trimoxazole-induced DRESS. HLA-B*52:01 was associated with co-trimoxazole-induced MPE.
CONCLUSIONS
CONCLUSIONS
Co-trimoxazole could induce various phenotypes of CADRs. Genotypic and phenotypic factors that may potentially predict co-trimoxazole-induced SCARs include male gender, HIV infection, prophylactic and prolonged drug use, as well as the presence of HLA-A*11:01, HLA-B*13:01, HLA-B*38:02, or HLA-DRB1*12:01 alleles.
Identifiants
pubmed: 37793359
pii: 000534342
doi: 10.1159/000534342
pmc: PMC10711762
doi:
Substances chimiques
Trimethoprim, Sulfamethoxazole Drug Combination
8064-90-2
HLA-DRB1 Chains
0
HLA-B Antigens
0
HLA-A Antigens
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
966-975Informations de copyright
© 2023 The Author(s). Published by S. Karger AG, Basel.
Références
Curr Drug Metab. 2000 Dec;1(4):391-404
pubmed: 11465045
Pharmacogenet Genomics. 2015 Aug;25(8):402-11
pubmed: 26086150
Pharmacogenomics J. 2014 Jun;14(3):281-8
pubmed: 24322785
CMAJ. 2011 Nov 8;183(16):1851-8
pubmed: 21989472
Drug Metab Pharmacokinet. 2022 Dec;47:100480
pubmed: 36379177
J Pharmacol Exp Ther. 2006 Oct;319(1):497-505
pubmed: 16857727
Am J Med. 2011 Jul;124(7):588-97
pubmed: 21592453
Drug Metab Dispos. 2015 Sep;43(9):1372-80
pubmed: 26138612
Pharmacogenomics. 2009 Apr;10(4):531-40
pubmed: 19374512
J Invest Dermatol. 2020 Aug;140(8):1659-1662.e6
pubmed: 31981579
Toxicology. 2005 Apr 15;209(2):131-4
pubmed: 15767025
Antimicrob Agents Chemother. 1997 Nov;41(11):2466-70
pubmed: 9371351
Front Pharmacol. 2020 Feb 27;11:78
pubmed: 32180714
Nature. 2004 Apr 1;428(6982):486
pubmed: 15057820
Front Pharmacol. 2016 Jul 18;7:186
pubmed: 27486401
N Engl J Med. 2013 Oct 24;369(17):1620-8
pubmed: 24152261
BMC Med Genomics. 2012 Jul 23;5:32
pubmed: 22824134
Pharmacogenet Genomics. 2017 Dec;27(12):429-437
pubmed: 28885988
Rev Infect Dis. 1982 Mar-Apr;4(2):426-8
pubmed: 6981160
Clin Pharmacol Ther. 1981 Aug;30(2):239-45
pubmed: 7249508
J Eur Acad Dermatol Venereol. 2015 Aug;29(8):1539-44
pubmed: 25491106
Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4134-9
pubmed: 15743917
Am J Clin Dermatol. 2001;2(3):151-8
pubmed: 11705092
Pharmacogenet Genomics. 2009 Sep;19(9):704-9
pubmed: 19696695
Pharmacogenet Genomics. 2006 Apr;16(4):297-306
pubmed: 16538176
N Engl J Med. 2008 Feb 7;358(6):568-79
pubmed: 18256392
Pharmacogenet Genomics. 2011 May;21(5):303-7
pubmed: 21301380
Indian J Anaesth. 2013 May;57(3):325-6
pubmed: 23983309
Clin Pharmacol Ther. 2020 Nov;108(5):1078-1089
pubmed: 32452529
Curr Allergy Asthma Rep. 2018 Mar 24;18(4):26
pubmed: 29574562
N Engl J Med. 1994 Nov 10;331(19):1272-85
pubmed: 7794310
J Allergy Clin Immunol. 2021 Apr;147(4):1402-1412
pubmed: 32791162
Pharmacogenomics. 2008 Nov;9(11):1617-22
pubmed: 19018717
Front Immunol. 2021 Apr 29;12:658593
pubmed: 33995375
Lancet. 2002 Mar 2;359(9308):727-32
pubmed: 11888582
J Clin Neurosci. 2011 Oct;18(10):1289-94
pubmed: 21802305
J Chin Med Assoc. 2016 Jun;79(6):314-9
pubmed: 27025225
Pharmacogenet Genomics. 2008 Feb;18(2):99-107
pubmed: 18192896
Epilepsia. 2010 May;51(5):926-30
pubmed: 20345939
Nephrol Dial Transplant. 2011 Nov;26(11):3567-72
pubmed: 21393610
Semin Immunopathol. 2016 Jan;38(1):75-86
pubmed: 26553194
PLoS One. 2016 Jun 07;11(6):e0156000
pubmed: 27272151
Clin Exp Allergy. 2015 Aug;45(8):1305-16
pubmed: 25851465
Arch Dermatol. 1987 Sep;123(9):1171-3
pubmed: 3477129